RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES. - BIM-001

Start Date11 Apr 2024

Sponsor / Collaborator

Genetic SpA

NCT06267274

/ RecruitingPhase 1

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Start Date01 Apr 2024

Sponsor / Collaborator

Amneal Intermediate, Inc.

[+1]

100 Clinical Results associated with Bimatoprost

100 Translational Medicine associated with Bimatoprost

100 Patents (Medical) associated with Bimatoprost

1,135

Literatures (Medical) associated with Bimatoprost

01 Aug 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

HPLC method for detecting prostaglandin F2α analogs in cosmetics: Optimization for chromatographic separation and sample preparation

Article

Author: Sung, Min Kyung ; Kim, Hyun-Kyung ; Shin, Eun Jin ; Kim, Hyung Soo ; Woo, In Suk ; Han, Kyoung-Moon ; Kim, You Kyung

Some prostaglandin F_2α (PGF_2α) analogs, including bimatoprost and tafluprost, are pharmaceutical substances known to cause specific abnormal reactions that promote eyelash growth. However, research on the simultaneous analysis of multiple PGF_2α analogs using HPLC-UV or DAD techniques is limited. In this study, a high-performance liquid chromatography (HPLC) method was developed for the simultaneous analysis of 11 PGF_2α analogs, optimizing both the analytical column and sample preparation method. Five columns with varying particle sizes, lengths, and packing types were compared to select the optimal analytical column. The separation efficiency of the columns was confirmed by comparing their chromatographic parameters, including retention time, resolution, number of theoretical plates, and height equivalent to a theoretical plate. Solid-phase extraction (SPE) was used to pretreat cosmetic samples, and the washing solvent and cartridge type for the SPE process were optimized. The established HPLC method was validated in terms of linearity, limits of detection and quantification, recovery, accuracy, and precision. The verified analytical method was applied to eyelash serums currently available in the market, and norbimatoprost was detected in one product. The HPLC method proposed in this study may help prevent the distribution of cosmetics containing illegal PGF_2α analogs.

01 May 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Treatment of glaucoma with drug-loaded contact lenses: A systematic review and meta-analysis

Review

Author: Cao, Wenbo ; Li, Jia ; Ren, Cong ; Yu, Mingkun ; Guo, Bin ; Zhang, Diya ; Wang, Xuan ; Bi, Hongsheng ; Xu, Zihang

OBJECTIVE:

This study is a systematical review regarding the glaucoma treatment with drug-loaded contact lenses. The effectiveness and safety about that were summarized, which providing effective suggestions and guidance for clinical research.

METHODS:

The studies published up to May 1, 2024 on the treatment of glaucoma with sustained-release contact lenses were searched from CNKI, Wanfang Data, VIP, PubMed, Embase, Cochrane Library, and Medline. CAMARADES was used to evaluate literature quality. The safety, endpoints of intraocular pressure reduction (IOPR) and duration of intraocular pressure (IOP) decline during glaucoma treatment were analyzed by means of qualitative and quantitative methods. The protocol registration number is CRD42024487157.

RESULTS:

47 studies were included. In clinical trials, glaucoma patients showed a 50% reduction in IOP and no corneal tissue destruction after wearing contact lenses. In animal experiments, the endpoint IOPR [MD = 0.58, 95%CI (0.37, 0.80), P < 0.00001] of the medicated contact lenses group was significantly better than that of the eye drops group. Subgroup analysis showed that contact lenses loaded with timolol (TML), with TML + dorzolamide, and with TML + latanoprost, which compared to eye drops, had a better effect on reducing IOP, while contact lenses loaded with puerarin, latanoprost, and TML + bimatoprost showed no statistical difference. Most studies demonstrated the duration of IOP reduction and drugs release in vitro for ≥3 days during contact lenses treatment.

CONCLUSION:

Most drug-loaded contact lenses exhibit excellent effectiveness and safety. The nanoparticle-loaded contact lenses containing TML for glaucoma treatment is recommended in future clinical research.

01 Apr 2025·DRUGS

Safety and Longevity of Intraocular Pressure Control After Bimatoprost Implant Administration: Interim Analysis of a Phase 3b Clinical Trial (TRITON)

Article

Author: Gous, Petrus ; Slabaugh, Mark ; Lascaratos, Gerassimos ; Caldwell, Delmar ; Wirta, David ; Bejanian, Marina ; Gupta, Shailesh ; Wallace, Dana ; Moster, Marlene ; Brinkmann, Christian ; Park, Abraham ; Christie, William C. ; Craven, E. Randy ; Bicket, Amanda ; Grupcheva, Christina ; Misheva, Aneta ; Kerr, Nathan ; Dzhelebov, Dimitar ; Bicket, Amanda K. ; Walters, Thomas ; Silverstein, Steven M. ; van Oterendorp, Christian ; Raczynska, Dorota ; Luebke, Jan ; Khaimi, Mahmoud ; Sarkisian, Steven ; Moyes, Andrew ; Maram, Jyotsna ; Basha, Mahdi ; Penkov, Milen ; Lind, John ; Cagini, Carlo ; Evans, Richard ; Teper, Slawomir ; Robinson, Michael R. ; Paauw, James ; Nolan, Daniel ; Lupinacci, Anahi ; Bourne, Rupert ; Schargus, Marc ; Segal, Bruce ; Martin, Elizabeth ; Dubois, Vincent ; Silverstein, Steven ; Sims, Annette ; Scorcia, Vincenzo ; Fichtl, Marek ; Christie, William ; Lerner, Simon Fabian ; Perez, Bernard ; Lubke, Jan ; Alaghband, Pouya ; Duzman, Eran ; Ivanova, Stanislava ; Kolko, Miriam ; Oddone, Francesco ; Zeolite, Carlos Ignacio ; Berdahl, John ; Paul, Matthew ; Cheeseman, Robert ; Santos, Rodrigo ; Gutmark, Ron ; Bercovich, Gabriel ; Moroi, Sayoko ; Vingolo, Enzo M. ; Daskalov, Veselin ; Zalewski, Dominik ; Milano, Giovanni ; Pu, Yongjia ; Pavicic-Astalos, Jasna ; Walman, Gerald ; Jerkins, Gary ; Wells, Tony ; Yanev, Petar ; Patel, Hemang ; Anguelov, Botio ; Gentile, Carolina ; Cantor, Louis ; Jiao, Jenny ; Hristozov, Valentin ; Topchiyska, Malina ; Jorgensen, Adam ; Cisiecki, Slawomir ; Blasberg, Robert ; Gous, Petrus N. J. ; Ansari, Husam ; Levin, Samantha ; Helsdingen, Nicolaas van ; Hopes, Marina ; Elfervig, John ; Brinkmann, Christian K. ; Bettis, Daniel ; Kubal, Aarup ; Shah, Manjool ; Logan, Dwayne ; Nguyen, Ashley ; Kammer, Jeffrey ; Hendrix, Jason

BACKGROUND:

Bimatoprost implant 10 µg is an intracameral, biodegradable implant that slowly releases bimatoprost to lower intraocular pressure (IOP). This study was designed to evaluate safety and the duration of the IOP-lowering effect after single and as-needed repeat administration of the bimatoprost implant in patients with open-angle glaucoma (OAG) and ocular hypertension (OHT).

PATIENTS AND METHODS:

This study is an interim analysis of an ongoing, prospective, open-label, multicenter study in patients with OAG or OHT who are inadequately managed with topical IOP-lowering medication for reasons other than efficacy. IOP-lowering rescue treatment is allowed if implant retreatment criteria are not met. The primary endpoint is time to retreatment/rescue after the initial implant administration analyzed with the Kaplan-Meier method. Key safety measures include treatment-emergent adverse events (TEAEs) and reading-center evaluation of central corneal endothelial cell density (CECD). Analysis of data collected through 15 September 2023 focused on outcomes after a single or two implants.

RESULTS:

In total, 441 patients received the 10-µg bimatoprost implant in the study eye on day 1 (cycle 1), 179 patients received a second administration (cycle 2), and 378 patients had at least 12 months of follow-up data available. The median time (95% confidence interval) from the first administration to a second administration or rescue was 392 (369, 485) days; the probability of not requiring retreatment or rescue by day 360 was 57.5%. A second implant administration similarly provided a long duration of IOP control. The baseline mean (standard error, SE) IOP was 25.6 (0.14) mmHg; the mean (SE) change from baseline IOP in unrescued eyes after a single administration was - 7.5 (0.21) mmHg at week 24 and - 6.4 (0.28) mmHg at month 12. Conjunctival hyperemia, typically associated with the administration procedure, was the most common ocular TEAE (cycle 1, 14.3%; cycle 2, 12.8%). Mean (SE) percentage change in CECD from baseline at 12 months after administration was - 4.3 (0.81)% in cycle 1 and - 8.5 (2.22)% in cycle 2. The cycle 1 implant was no longer visible or ≤ 25% of initial size in 66.3% and 94.3% of study eyes at months 12 and 24, respectively.

CONCLUSIONS:

In this interim analysis based on available data, the IOP-lowering effect of the initial administration of the 10-µg bimatoprost implant was well maintained for > 1 year in most patients. Results after a second administration were comparable. The safety profile of initial and repeat administration was acceptable.

TRIAL REGISTRY:

ClinicalTrials.gov identifier NCT03850782; registered 20 February 2019.

News (Medical) associated with Bimatoprost

19 Mar 2025

·www.globenewswire.com

Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial

Press Release Nicox Announces Last Patient Completes Final Visit in NCX 470 Phase 3b Whistler Glaucoma Trial Results expected in May 2025 Last patient in the U.S. in the ongoing NCX 470 Denali Phase 3 trial has also completed their last visit and results remain on track for Q3 2025 March 19, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient completed their final visit in the Whistler Phase 3b clinical trial investigating the dual mechanism of action (nitric oxide and prostaglandin analog) of NCX 470 in intraocular pressure (IOP) lowering. The Whistler Phase 3b trial enrolled 18 healthy volunteers with ocular hypertension in a double-masked, placebo-controlled study investigating the action of NCX 470 on aqueous humor parameters including trabecular meshwork outflow and episcleral venous pressure. Each subject participated in the trial for approximately 8 days.About NCX 470NCX 470, Nicox’s lead clinical product candidate, is a novel NO-donating bimatoprost eye drop, currently in Phase 3 clinical development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. Results of Mont Blanc, the first of the two Phase 3 clinical trials, have been extensively published and are available on our website. The second Phase 3 clinical trial, Denali, is currently ongoing. The last American patient in Denali has completed their final visit, with Chinese patients completing theirs, and the results are expected in Q3 2025. Mont Blanc and Denali have been designed to fulfill the regulatory requirements for safety and efficacy Phase 3 trials to support NDA submissions in both the U.S. and in China, where NCX 470 is exclusively licensed to Ocumension Therapeutics. NCX 470 is also licensed exclusively to Kowa for Japan. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_WhistlerLPLV_19March2025_PR_FINAL

Phase 3

06 Feb 2025

·www.businesswire.com

MediPrint Ophthalmics Advances Glaucoma Program, Expands Patent Portfolio, and Prepares for Key Industry Presentation

SAN DIEGO--( BUSINESS WIRE )--MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company, continues to advance its innovative glaucoma program following the successful completion of its Phase 2b clinical trial for LL-BMT1. As the company progresses towards the next phase of development, MediPrint anticipates meeting with the U.S. Food and Drug Administration (FDA) in 2025 to discuss preparations for Phase 3 clinical studies. Regulatory Progress and Path Toward Phase 3 Following the promising results from its Phase 2b trial, MediPrint remains committed to bringing LL-BMT1 to market as a novel drug delivery platform for the treatment of glaucoma and ocular hypertension. The company expects to engage with the FDA in 2025 to align regulatory requirements and define the pathway for Phase 3 studies. LL-BMT1’s sustained drug delivery approach via a 3D-printed, drug-eluting contact lens offers a potential paradigm shift in glaucoma care by significantly reducing treatment burden and enhancing patient compliance. The study demonstrated that LL-BMT1 provided similar therapeutic results as a once-a-week solution to the comparator, 0.01% bimatoprost eye drop, offering a significant dosing advantage over one or multiple-times-per-day eye drop regimens. Expansion of Patent Portfolio: Extending Innovation and Leadership MediPrint has further solidified its intellectual property portfolio with the recent issuance of U.S. Patent No. 12,178,904 by the U.S. Patent and Trademark Office on December 31, 2024. This patent, which covers MediPrint’s proprietary chemistry related to the sustained delivery of prostaglandins from contact lenses, extends the company’s patent protection through 2043. The prostaglandin evaluated in LL-BMT1 was bimatoprost, a well-established treatment for lowering intraocular pressure in glaucoma patients. With this milestone, MediPrint’s global patent portfolio now encompasses 29 granted patents, with additional patents pending. This robust intellectual property estate reinforces the company’s leadership in ophthalmic drug delivery and underscores its commitment to pioneering innovative solutions for the treatment of ocular diseases. Upcoming Presentation at Glaucoma 360 New Horizons Forum MediPrint is also pleased to announce its participation in the upcoming Glaucoma Research Foundation’s annual meeting, the Glaucoma 360 New Horizons Forum, taking place this week in San Francisco. The company will present its latest developments in sustained drug delivery technology and discuss how LL-BMT1 could redefine the standard of care for patients with glaucoma. “ Our continued progress in both clinical development and intellectual property expansion reflects MediPrint’s unwavering commitment to innovation in ophthalmic drug delivery,” said Praful Doshi, Founder and CEO of MediPrint Ophthalmics. “ As we prepare for regulatory discussions and advance towards Phase 3, we remain focused on delivering transformative solutions that improve patient outcomes.” About MediPrint® Ophthalmics MediPrint® Ophthalmics is a San Diego-based clinical-stage eye care pharmaceutical company dedicated to enhancing vision for life. The company is pioneering drug-eluting contact lenses that deliver therapeutics directly to the eye, providing comfortable, convenient, preservative-free alternatives to traditional eye drop treatments. MediPrint’s portfolio is designed to address major eye conditions, including glaucoma, myopia, dry eye, and discomfort associated with contact lens use. For more information, please visit www.mediprintlens.com .

Clinical ResultPhase 2Phase 1Phase 3

28 Jan 2025

·www.globenewswire.com

Nicox Announces Scientific Presentation and Conference Attendance in H1 2025

Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025January 28, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced a presentation at the upcoming American Glaucoma Society (AGS) Annual Meeting 2025 and participation in a number of key ophthalmology and financial conferences in the first half of 2025. Presentation of additional analysis of the NCX 470 Mont Blanc Phase 3 Clinical trial AGS 2025 Annual Meeting – February 26 to March 2, 2025, Washington, U.S. Poster Title: Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC TrialType: Poster Presentation Session Date: Saturday March 1, 2025 from 7:00 am to 8:00 am (local time). Presenter: Dr. Robert Fechtner, Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY Upcoming Conference Attendance Allinvest securities Biomed Forum – February 4, 2025 – Paris, France Investor Access – April 1-2, 2025 – Paris, France Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting – May 4-8, 2025 – Salt Lake City, Utah, U.S.BIO International Convention – June 16-19, 2025 – Boston, MA, U.S. Members of the management team will be available for one-on-one meetings at these events. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.com Analyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_H1_2025_CONFERENCES_PR_FINAL

Phase 3

100 Deals associated with Bimatoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D02724	Bimatoprost	S01EE03	DB00905

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Takeda Pharmaceutical Co., Ltd.	07 Jul 2009
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	07 Jul 2009
Hypotrichosis	United States	AbbVie, Inc.	24 Dec 2008
Glaucoma, Open-Angle	United States	AbbVie, Inc.	16 Mar 2001
Ocular Hypertension	United States	AbbVie, Inc.	16 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cataract	Phase 2	United States	SpyGlass Pharma IncStartup	13 Oct 2023
Alopecia, Male Pattern	Phase 2	United States	Allergan UC	01 Aug 2013
Alopecia	Phase 2	United States	Allergan UC	01 Jun 2011
Alopecia	Phase 2	Germany	Allergan UC	01 Jun 2011
Androgenetic Alopecia	Phase 2	United States	Allergan UC	01 Jun 2011
Androgenetic Alopecia	Phase 2	Germany	Allergan UC	01 Jun 2011
Cutis Laxa	Phase 1	United States	Allergan UC	01 Nov 2016

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03850782 (TRITON, Pubmed \| Drugs)	Phase 3	Ocular Hypotension	441	Bimatoprost implant 10 µg	ldxobxrjjj(zbzoqumqkr) = tvgyvcrsih pblkckedid (iqizgcoxxr, 369 - 485) View more	Positive	22 Feb 2025
NCT04747808 (BusinessWire) Manual	Phase 2	Glaucoma	-	LL-BMT1 32-µg dose	ekybwvcdqb(vhryooiegp) = rzxefxpcqz wrxxmzmiym (midmwojpvp ) View more	Positive	12 Nov 2024
NCT04747808 (BusinessWire) Manual	Phase 2	Glaucoma	-	bimatoprost 0.01%	-	Positive	12 Nov 2024
NCT03825380 (CTgov)	Phase 3	Glaucoma	485	Bimatoprost (T4032)	thltwweklj(dhzknrklnj) = lmbuxydsru essvtjkkqe (zregktfjnt, 0.19) View more	-	21 Nov 2023
NCT03825380 (CTgov)	Phase 3	Glaucoma	485	Lumigan® (Lumigan®)	thltwweklj(dhzknrklnj) = jmqhpwwczs essvtjkkqe (zregktfjnt, 0.18) View more	-	21 Nov 2023
NCT04285580 (CTgov)	Phase 3	Glaucoma, Open-Angle	37	Bimatoprost SR (Bimatoprost SR 10 μg)	xevlfxmsdt(wjfutcxqim) = rirahhayvt bdlyifzzat (llrkvtpbpj, 5.65) View more	-	08 Jun 2023
NCT04285580 (CTgov)	Phase 3	Glaucoma, Open-Angle	37	LUMIGAN (LUMIGAN 0.01%)	xevlfxmsdt(wjfutcxqim) = rsndwzeuem bdlyifzzat (llrkvtpbpj, 5.27) View more	-	08 Jun 2023
NCT01157364 \| NCT02250651 \| NCT02247804 (Pubmed)	Phase 3	Ocular Hypertension \| Glaucoma, Open-Angle	-	Bimatoprost implant 10 µg	pptgdwpzxm(psovqyxszz) = iuvtxoxfud dxjmwfurpo (lhvmgvcowt )	-	28 May 2022
NCT01157364 \| NCT02250651 \| NCT02247804 (Pubmed)	Phase 3	Ocular Hypertension \| Glaucoma, Open-Angle	-	Topical timolol maleate 0.5%	pptgdwpzxm(psovqyxszz) = yaipqnyfnw dxjmwfurpo (lhvmgvcowt )	-	28 May 2022
ARVO2022	Not Applicable	Glaucoma	122	Bimatoprost SR	wphivobhsp(byxfyafawc) = cfxkxupgqp uudwfbhevw (qhmqkzhnag )	-	01 May 2022
NCT03850782 (Phase 3b Study, ARVO2022)	Phase 3	Ocular Hypotension	203	Bimatoprost implant	xdaqnxzlwe(whhfnoxgwm) = euauntrxhc codreyapud (fwesrellpp )	-	01 May 2022
ARVO2022	Not Applicable	-	-	Bimatoprost free acid	ppdfeotspj(nbaavcifvk) = a dose-dependent although non-statistically significant increase in protein expression with a maximal increase of 56% nnombzqhve (bcbdyyqxqo ) View more	-	01 May 2022
ARVO2022	Not Applicable	Glaucoma	122	Bimatoprost SR implantation	ynegnbqtlp(rgentslfhr) = wljlettbtc acplcybwdt (ezuekrlhce )	-	01 May 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bimatoprost

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation